Pregnancy Clinical Trial
BACKGROUND: Pre-eclampsia complicates about 2% of pregnancies. It accounts for at least 50
000 maternal deaths per year worldwide and is the second most common cause of maternal death
in the developing world. Also, Pre-eclampsia is the commonest cause of iatrogenic
prematurity, It frequently coexists with intrauterine growth restriction (IUGR) and
placental abruption, other important causes of adverse prenatal outcome.
There have been many studies investigating whether the disease can be prevented. In order to
achieve this, one needs to be able to identify firstly those women that are at highest risk
of the disease.
Early studies showed that impedance to flow in the uterine arteries decreases with gestation
in normal pregnancies, while in pregnancies with established pre-eclampsia or IUGR the
impedance is increased.
These observations led to a number of screening studies in the second trimester, which
assessed if it is possible to predict those pregnancies destined to have complications of
impaired placentation. These studies showed that women with increased impedance to uterine
artery blood flow have an increased risk of developing pre-eclampsia, and detection can be
further increased by using angiogenic factors (That are involved in the pathogenesis of Pre-
eclampsia and could be useful for early prediction of the disease: VEGF, PIGF, PP13, sFLT1)
in combination with uterine arteries Doppler study in the second trimester.
METHODS: In this study we would like to add uterine arteries Doppler to the early routine
detailed ultrasound examination (14-16 weeks), in 3000 women in Jerusalem. in addition we
would like to check angiogenic factors from the serum blood taken for the routine triple
test in these women (16-18 weeks).pregnancy outcome would be collected after labour from the
medical centers participating in this research.
n/a
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03442582 -
Afluria Pregnancy Registry
|
||
| Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
| Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
| Enrolling by invitation |
NCT05415371 -
Persistent Poverty Counties Pregnant Women With Medicaid
|
N/A | |
| Completed |
NCT04548102 -
Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman
|
N/A | |
| Completed |
NCT03218956 -
Protein Requirement During Lactation
|
N/A | |
| Completed |
NCT02191605 -
Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy
|
N/A | |
| Completed |
NCT02223637 -
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
|
||
| Recruiting |
NCT06049953 -
Maternal And Infant Antipsychotic Study
|
||
| Completed |
NCT02577536 -
PregSource: Crowdsourcing to Understand Pregnancy
|
||
| Not yet recruiting |
NCT06336434 -
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT04786587 -
Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
|
||
| Not yet recruiting |
NCT05412238 -
Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months
|
N/A | |
| Not yet recruiting |
NCT05028387 -
Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
|
||
| Completed |
NCT02783170 -
Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women
|
Phase 4 | |
| Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 | |
| Recruiting |
NCT02507180 -
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
|
||
| Recruiting |
NCT02564250 -
Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women
|
N/A | |
| Recruiting |
NCT02619188 -
Nutritional Markers in Normal and Hyperemesis Pregnancies
|
N/A | |
| Completed |
NCT02528136 -
The Clinical Carbetocin Myocardium Trial
|
Phase 4 |